The Cooper Companies, Inc.

The Cooper Companies, Inc. Earnings Recaps

COO Health Care 2 recaps
Q1 2026 Mar 6, 2026

Cooper Companies reported a strong Q1 2026, driven by robust sales growth in its CooperVision segment and significant operational efficiencies, resulting in heightened earnings and free cash flow.

Key takeaways
  • Consolidated revenues reached $1.024 billion, reflecting a 6.2% year-over-year increase, with CooperVision achieving 7.6% growth.
  • Non-GAAP earnings per share rose 20% to $1.10, exceeding guidance expectations.
  • Free cash flow totaled $159 million, allowing for increased guidance on both earnings and cash flow for the year.
  • Product launches, particularly within the MyDay portfolio, contributed significantly to market share gains, especially in the Americas and EMEA regions.
  • The strategic review process is ongoing, focused on maximizing long-term shareholder value amidst strong operational momentum.
Q4 2025 Dec 5, 2025

Cooper Companies reported a strong Q4 2025 with revenues reaching $1.065 billion, marking an organic growth of 3.4%. The company continues to demonstrate robust earnings growth and commitment to shareholder returns through substantial stock repurchases.

Key takeaways
  • Q4 revenues increased 4.6% year-over-year, with CooperVision revenues of $710 million, driven by improved MyDay availability despite some market softness in China.
  • Non-GAAP earnings grew 11% to $1.15, achieving the eighth consecutive quarter of beating consensus expectations.
  • Free cash flow for Q4 totaled $150 million, contributing to an updated target of over $2.2 billion for fiscal 2026-2028.
  • Nearly $200 million of stock was repurchased in Q4, with plans to allocate a similar percentage of free cash flow to share buybacks in fiscal 2026.
  • A formal strategic review has been initiated to explore long-term shareholder value opportunities, alongside enhancements to executive performance metrics linked to total shareholder return.